Publication Name	World Journal of Hepatology
Manuscript ID	25989
Country	Japan

Received	2016-03-28 15:32
Peer-Review Started	2016-03-28 17:32
To Make the First Decision	2016-05-17 12:19
Return for Revision	2016-05-18 11:13
Revised	2016-05-28 13:24
Second Decision	2016-06-13 16:57
Accepted by Journal Editor-in-Chief	2016-06-16 22:01
Accepted by Company Editor-in-Chief	2016-06-29 09:58
Articles in Press	2016-06-29 09:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-12 18:38
Publish the Manuscript Online	2016-07-22 10:22

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	New horizon for radical cure of chronic hepatitis B virus infection
Manuscript Source	Invited Manuscript
All Author List	Kazuto Tajiri and Yukihiro Shimizu
Funding Agency and Grant Number
Corresponding Author	Yukihiro Shimizu, MD, PhD, Gastro­enterology Center, Nanto Municipal Hospital, 938 Inami, Toyama 932-0211, Japan. rsf14240@nifty.com
Key Words	Covalently-closed circular DNA; Genome editing technology; Immune response; Immunotherapy; Program death-1; Interferon-γ; Tumor necrosis factor-α
Core Tip	Among the agents used to treat chronic hepatitis B virus (HBV) infection are nucleos(t)ide an-alogues, which have been shown to strongly suppress HBV replication. HBV replication, however, may be reactivated after cessation of treatment, because com-plete removal of covalently-closed circular DNA (cccDNA) from hepatocyte nuclei is extremely difficult. Immune responses have been shown to destroy cccDNA, but immune response alone is insufficient for complete eradication of template DNA. Several drugs were recently developed to block the HBV life cycle in hepa-tocytes, with drugs targeting cccDNA being, at least theoretically, the most effective for radical cure of chronic HBV infection. The safety of these agents should be extensively examined before their use in patients. Combinations of two or more classes of agent may be necessary for radical cure of chronic HBV infection.
Publish Date	2016-07-22 10:22
Citation	Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873
URL	http://www.wjgnet.com/1948-5182/full/v8/i21/863.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i21.863

Full Article (PDF)	WJH-8-863.pdf
Full Article (Word)	WJH-8-863.doc
Manuscript File	25989-Review.docx
Answering Reviewers	25989-Answeing reviewers.pdf
Audio Core Tip	25989-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	25989-Conflict-of-interest statement.pdf
Copyright License Agreement	25989-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25989-Language certificate.pdf
Journal Editor-in-Chief Review Report	25989-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	25989-Scientific misconduct check.pdf
Scientific Editor Work List	25989-Scientific editor work list.pdf